Department of Orthopedics, The Third Affiliated Hospital of Chongqing Medical University, Chongqing, P.R. China.
Department of Orthopedics, The University-Town Hospital of Chongqing Medical University, Chongqing, P.R. China.
Bioengineered. 2021 Dec;12(1):5870-5882. doi: 10.1080/21655979.2021.1967034.
Although osteosarcoma (OS) is the most common malignant tumor among juvenile bone tumors, its treatment plan and clinical outcome have not improved significantly in recent decades. Tetrandrine (TET), a Chinese medicine that is usually used in the therapy of silicosis, hypertension and arthritis, has been confirmed by many studies to possess potent antitumour growth properties, but there are different limitations when describing specific mechanisms. Here, we found that TET can obviously prevent the proliferation, migration and invasion of both 143B and MG63 cells and promote their apoptosis in vitro. Our results for luciferase reporter and Western blotting assays show that TET may exert its antitumour activity by regulating multiplex signaling pathways, including the MAPK/Erk, PTEN/Akt, Juk and Wnt signaling pathways. Furthermore, the regulatory effect of TET on OS cells and related signaling pathways was verified again in vivo. Our findings suggest that the anticancer function of TET on human OS may be mediated by its targeting of multiple signaling pathways and that TET may be used as a single drug or in combination with other drugs during the treatment of OS.
虽然骨肉瘤（OS）是青少年骨肿瘤中最常见的恶性肿瘤，但近几十年来，其治疗方案和临床结果并没有显著改善。汉防己甲素（TET）是一种常用于治疗矽肺、高血压和关节炎的中药，已被多项研究证实具有很强的抗肿瘤生长特性，但在描述具体机制时存在不同的局限性。在这里，我们发现 TET 可以明显抑制 143B 和 MG63 细胞的增殖、迁移和侵袭，并促进其体外凋亡。我们的荧光素酶报告基因和 Western blot 检测结果表明，TET 可能通过调节多条信号通路，包括 MAPK/Erk、PTEN/Akt、Juk 和 Wnt 信号通路，发挥其抗肿瘤活性。此外，TET 对 OS 细胞及相关信号通路的调节作用在体内也得到了再次验证。我们的研究结果表明，TET 对人骨肉瘤的抗癌作用可能是通过其对多种信号通路的靶向作用介导的，TET 可能在骨肉瘤的治疗中作为单一药物或与其他药物联合使用。
